Preliminary data from an open-label phase II trial which enrolled 15 patients with relapsed/refractory SCLC reported promising data with clinical benefit in four patients treated with ieramilimab (anti-LAG3) and spartalizumab (anti-PD-1) (NCT03365791) [150]. Here, LAG3 is linked to small cell lung carcinoma.